公开(公告)号：US20190282572A1

公开(公告)日：2019-09-19

申请号：US16345157

申请日：2017-10-26

Applicant: H. LundbeckA/S

Inventor： Jan Kehler ,  Lar Kyhn Rasmussen ,  Morten Langgård ,  Mikkel Jessing ,  Paulo Jorge Vieira Vital ,  Karsten Juhl

IPC: A61K31/4985 ,  A61K31/553 ,  A61K31/5377 ,  A61K45/06 ,  A61P25/28 ,  A61P25/16

Abstract: The present invention provides combination treatments comprising administration of compounds that are PDE1 enzyme inhibitors and other compounds useful in the treatment of neurodegenerative disorders such as for example Alzheimer's Disease, Parkinson's Disease or Huntington's Disease. Separate aspects of the invention are directed to the combined use of said compounds for the treatment of neurodegenerative and/or cognitive disorders. The present invention also provides pharmaceutical compositions comprising said PDE1 enzyme inhibitors together with other compounds useful in the treatment of neurodegenerative disorders.

公开(公告)号：US11691975B2

公开(公告)日：2023-07-04

申请号：US17343227

申请日：2021-06-09

Applicant: H. Lundbeck A/S

Inventor： Cheryl A. Grice ,  Daniel J. Buzard ,  Michael B. Shaghafi

IPC: A61K31/438 ,  A61K31/407 ,  C07D471/10

CPC classification number: C07D471/10

Abstract: Provided herein are spirocyclic and fused bicyclic carbamates and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful as modulators of MAGL. Furthermore, the subject compounds and compositions are useful for the treatment of pain.